Eli Lilly and Co. and Merck have extended an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s ALIMTA (pemetrexed for injection) and Merck’s KEYTRUDA (pembrolizumab) in a Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details were not disclosed. The expansion of this onco...